Target intelligence / Profile preview

Cellular tumor antigen p53 (TP53) N-terminal transactivation domain (TP53 TAD)

Target
TP53 TAD
Molecular classification
Transcription factor, Tumor suppressor
01

Overview

The TP53 N-terminal regulatory region, primarily consisting of the transactivation domain (TAD), is a vital segment of the p53 tumor suppressor protein responsible for mediating its transcriptional activity. This region, which includes residues 1–61, acts as a scaffold for recruiting co-activators and the basal transcription machinery, enabling p53 to regulate genes involved in cell cycle arrest, DNA repair, and apoptosis (UniProt P04637). It is also the primary site for interaction with negative regulators such as MDM2 and MDMX, which bind to the N-terminus to inhibit p53 function and promote its degradation (PMID: 25210018). In many cancers where p53 remains wild-type, its activity is often suppressed by MDM2 overexpression, making the p53-MDM2 interface a high-priority therapeutic target. Small-molecule inhibitors like Idasanutlin and Navtemadlin are designed to disrupt this interaction by mimicking the p53 N-terminal residues, thereby stabilizing p53 and restoring its tumor-suppressive capabilities (PMID: 30104365). While promising, these therapies are often limited by hematological toxicities and are generally effective only in patients with wild-type TP53 (PMID: 33009416).

Other names
p53 N-terminal domainp53 transactivation domainp53 TADp53 N-terminal regulatory regionTumor protein p53 N-terminus
02

Mechanism of action

Restoration of p53 activity by inhibiting the protein-protein interaction between the p53 N-terminal transactivation domain and the E3 ubiquitin ligase MDM2.

03

Biological functions

Cell cycle arrestApoptosisDNA repairSenescenceMetabolic regulation
04

Disease associations

CancerLi-Fraumeni syndrome
05

Safety considerations

ThrombocytopeniaNeutropeniaGastrointestinal toxicityPotential for secondary TP53 mutations
06

Interacting drugs

Idasanutlin

6 more in the full profile.

07

Biomarkers

TP53 wild-type statusMDM2 amplificationp21 (CDKN1A) expressionMIC-1 (GDF15) serum levels

Beyond the preview

Go deeper on Cellular tumor antigen p53 (TP53) N-terminal transactivation domain (TP53 TAD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular tumor antigen p53 (TP53) N-terminal transactivation domain (TP53 TAD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call